However, it should be taken into account that the effects of AZA in the expression of immunomodulatory signatures are diverse and additional aspects might be involved in boosting the anti-tumor immune responses mediated by anti-PD-L1 and anti-CTLA4 treatments, as explained below. This evidence concerns the gene CTLA4 and neoplasm.